Plasmid DNA Manufacturing Market Emerging Growth 2019? Cobra Biologics and Pharmaceutical Services, VGXI, Inc., Aldevron, Kaneka Corporation, Nature Technology Corporation, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult

Increasing number of patients opting for gene therapy is a major factor driving growth of the plasmid DNA manufacturing market. Gene therapy is a leading field in medical science, which promises new treatment development for patients suffering from various diseases.

For instance, Adeno-associated AAV2 vectors carrying therapeutic gene (RPE65) intra-retinal injection leads to improved vision of individuals suffering from Leber’s Congenital Amaurosis.

Several clinical trials are being conducted on viral vectors and plasmid DNA manufacturing that are focused on the potential of gene therapy. Increasing investments in drug development and commercialization of these therapies in order to meet significant medical needs are factors driving the market growth. These genetic markers are associated with complex diseases, therefore it is important to study about the genetic information and its clinical application in designing clinical trials and gene therapy product manufacturing.

Purchase this Premium Report @ https://www.coherentmarketinsights.com/insight/buy-now/2593

According to a data published by the Journal of Gene Medicine: March 2018, till November 2017, an estimated 2,600 gene therapy clinical trials were ongoing, have been completed, or have been approved in 36 countries. Countries where the trials were conducted include the U.S., the U.K., Australia, Canada, China, France, Germany, Japan, Switzerland, the Netherlands, and others. Moreover, diseases targeted by gene therapies include cardiovascular diseases, cancer, inflammatory and infectious diseases, Hemophilia A and B, Severe Combined Immunodeficiency (SCID), ocular diseases, neurological diseases, and others.

Europe region is expected to witness significant growth in the plasmid DNA manufacturing market due to adoption of strategies such as collaboration by the market players. For instance, in May 2018, PlasmidFactory GmbH & Co. KG collaborated with Sirion-Biotech GmbH, Vibalogics GmbH, and PROGEN for adeno-associated virus (AAV) vector manufacturing. This collaboration was done to accelerate timeline and to create easy workflow from plasmid manufacturing to GMP production, and analytics of recombinant AAV to fulfil the customers' requirement of AAV vector.

Major players operating in the global plasmid DNA manufacturing market include Cobra Biologics and Pharmaceutical Services, VGXI, Inc., Aldevron, Kaneka Corporation, Nature Technology Corporation, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, and Waisman Biomanufacturing.

Free Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/2593

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.